Treatment Patterns and Perceptions of Treatment Options in Japanese Pediatric and Adolescent Patients with Atopic Dermatitis
Open Access
- 18 April 2026
- journal article
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (7) , 2977-2995
Abstract
Atopic dermatitis (AD) is a relapsing, chronic inflammatory skin condition characterized by intense itching and eczematous lesions. AD is common in pediatric patients, but treatment options are limited for these patients and data on treatment patterns are scarce. This study aimed to descriptively evaluate treatments used in pediatric AD and physician- and patient-reported perspectives of available options in real-world practice in Japan. Data were drawn from the Adelphi Real World Pediatric and Adolescent AD Disease Specific Programme™, a cross-sectional survey, with retrospective data collection, of physicians and patients in Japan from July to December 2022. Physicians completed patient record forms for their next 3-10 consecutively consulting patients, collecting data on demographics and clinical characteristics, treatment regimens, and perceptions around treatment choice and satisfaction. Patients/caregivers also provided their perceptions on treatment choice and satisfaction. Analyses were descriptive. Overall, 55 physicians provided data for 537 pediatric patients, with 111 patients/caregivers also reporting data. The patient population was 63.3% (n = 340) male, and mean ± standard deviation age was 12.6 ± 4.2 years, with 54.0% (n = 290) of patients classified as pediatric (aged ≤ 14 years) and 46.0% (n = 247) adolescent (aged 15-17 years). Patient treatments included topical corticosteroids (TCS; 89.1%, n = 457/513), biologics (12.3%, n = 63/513), oral JAK-is (7.6%, n = 39/513), and immunosuppressants (1.8%, n = 9/513). Physicians reported that they believe better control could be achieved in 64.8% (n = 332) of patients compared with 93.1% (n = 81) of patients self-reporting this. TCS was the most common treatment in pediatric AD management, in agreement with the current guideline recommendation. Overall, most physicians and patients believed that better control could be achieved. However, in mild patients, most patients believed better control could be achieved, while physicians did not. This suggests that views of disease control, and desire for improved disease control, may differ between physicians and patients.Keywords
This publication has 46 references indexed in Scilit:
- Bridging the Gap: Comparing Patient-Clinician Views on Treatment Goals and Communication in the Management of Atopic Dermatitis Within the Asia–Pacific RegionDermatology and Therapy, 2024
- Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2023
- Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in JapanDermatology and Therapy, 2022
- The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysisEuropean Journal of Clinical Pharmacology, 2022
- Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2022
- Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and CanadaDermatology and Therapy, 2021
- Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2021
- Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic DermatitisDermatology and Therapy, 2021
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020
- The Patient-Oriented Eczema MeasureArchives of Dermatology, 2004